THE EFFECT OF TRI‐POTASSIUM DI‐CITRATO BISMUTHATE (DE‐NOL) ON THE HEALING OF CHRONIC DUODENAL ULCERS

Abstract

Forty‐six patients suffering from chronic duodenal ulcer, proven endoscopically, were treated in a randomized double‐blind cross‐over trial with either tri‐potassium di‐citrato bismuthate (De‐Nol) or placebo for four weeks and assessed symptomatically and endoscopically. Those patients who failed to heal after treatment with either agent were crossed over to the alternative preparation and reassessed after a further 28 days. Forty‐two patients completed the study involving 57 patient treatments. A highly significant improvement in both symptomatic response (P$lt0$md01) and endoscopic healing (P$lt0$md01) was seen in those patients receiving tri‐potassium di‐citrato bismuthate (De‐Nol) as against placebo therapy.